Media

Rebranding reflects value of company's technology in drug discovery

Manchester, UK, July 8 2013 – To reflect an increased recognition of the impact of its 3D NMR technology on drug discovery and optimisation, C4X Discovery has been chosen as the new name for Conformetrix.

Company investigating selective orexin-1 receptor inhibitors

Manchester, UK, December 17 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, is pleased to announce progress in its lead proprietary programme, focused on selective inhibition of the orexin-1 receptor (OX1R). The company has generated a series of potent antagonists, which it plans to evaluate and progress to drug leads. Orexin is a neurotransmitter believed to play a role in a broad range of behavioural conditions, from sleep disorders to addiction.

Manchester, UK, December 5 2012 – The CEO of Conformetrix Ltd, a leader in optimising drug discovery and design, will discuss partnering strategies and the impact of deals at the One Nucleus Genesis 20121 conference in London on December 13. Dr Sam Williams will also take part in the pre-Genesis 2012 Seminar and BioNewsRound Award2 the day before the conference.

Conference to highlight vibrant life sciences sector in Northern England

Manchester, UK, November 5 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, will take part in a panel discussion on big pharma partnering at BioCap 20121 in Manchester on November 6 2012.

Manchester, UK, October 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, has expanded its medicinal chemistry team with the appointment of an experienced pharmaceutical researcher. Dr Thorsten Nowak joins from AstraZeneca, where he worked for 16 years in drug design and project management.

Company to discuss conformational insights

Manchester, UK, September 3 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, will be presenting at ELRIG Drug Discovery 20121 on September 6 2012. The presentation, 'The application of ligand conformational preferences in drug discovery', will discuss how the tuning of conformational preferences can be used to optimise the potency of drug candidates.

First collaborative deal for Conformetrix

Manchester and London, UK, April 16 2012 – Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix’s proprietary NMR-based technology will be applied across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

Manchester, UK, March 7 2012 – The Board of Conformetrix Ltd, a leader in optimising drug discovery and design, has appointed Dr Sam Williams as Chief Executive Officer, it is announced today.